A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...
Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s ...
ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered ...
Union Minister of State for Health and Family Welfare, Smt Anupriya Singh Patel recently delivered the keynote address at the 2nd DHR-ICMR Health Research Excellence Summit 2025. Dr V ...
Saudi Arabia’s investments in preventive cardiology and AI-assisted diagnostics, along with increasing awareness of ...
Crop biotechnology is like giving plants superpowers! It’s using science to make plants better, like helping them fight off ...
Nucleic acid testing (NAT) identifies specific pathogen genetic material (DNA or RNA), enabling early and precise diagnosis ...
Zacks Small Cap Research on MSN
DYAI: Purchase Orders Rolling In
DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic Applied BioSolutions, Inc. (NASDAQ:DYAI) announced third quarter 2025 results on November 12th, 2025, and held a conference call to discuss them after ...
Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...
According to Nova One Advisor, the global 3D bioprinting market size is calculated at USD 2.92 billion in 2025 and is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback